We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The first therapeutic effect data of VV116, a small-molecule oral drug for COVID-19 of Junshi Biosciences and Vigonvita, was released this week, captivating the industry.
News about the progress of Chinese small-molecule oral antiviral drug for COVID-19 has been disclosed in recent days and the related R&D ushers in a critical point.